These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8636778)

  • 1. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.
    Boote DJ; Dennis IF; Twentyman PR; Osborne RJ; Laburte C; Hensel S; Smyth JF; Brampton MH; Bleehen NM
    J Clin Oncol; 1996 Feb; 14(2):610-8. PubMed ID: 8636778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.
    Visani G; Milligan D; Leoni F; Chang J; Kelsey S; Marcus R; Powles R; Schey S; Covelli A; Isidori A; Litchman M; Piccaluga PP; Mayer H; Malagola M; Pfister C
    Leukemia; 2001 May; 15(5):764-71. PubMed ID: 11368437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
    Chico I; Kang MH; Bergan R; Abraham J; Bakke S; Meadows B; Rutt A; Robey R; Choyke P; Merino M; Goldspiel B; Smith T; Steinberg S; Figg WD; Fojo T; Bates S
    J Clin Oncol; 2001 Feb; 19(3):832-42. PubMed ID: 11157037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.
    Yahanda AM; Alder KM; Fisher GA; Brophy NA; Halsey J; Hardy RI; Gosland MP; Lum BL; Sikic BI
    J Clin Oncol; 1992 Oct; 10(10):1624-34. PubMed ID: 1403040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420.
    Lee EJ; George SL; Caligiuri M; Szatrowski TP; Powell BL; Lemke S; Dodge RK; Smith R; Baer M; Schiffer CA
    J Clin Oncol; 1999 Sep; 17(9):2831-9. PubMed ID: 10561359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [SDZ PSC 833: a novel modulator of MDR].
    Covelli A
    Tumori; 1997; 83(5 Suppl):S21-4. PubMed ID: 9446255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
    Kornblau SM; Estey E; Madden T; Tran HT; Zhao S; Consoli U; Snell V; Sanchez-Williams G; Kantarjian H; Keating M; Newman RA; Andreeff M
    J Clin Oncol; 1997 May; 15(5):1796-802. PubMed ID: 9164187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia.
    Bauer KS; Karp JE; Garimella TS; Wu S; Tan M; Ross DD
    Leuk Res; 2005 Mar; 29(3):263-71. PubMed ID: 15661261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours.
    Pein F; Pinkerton R; Berthaud P; Pritchard-Jones K; Dick G; Vassal G
    Eur J Cancer; 2007 Sep; 43(14):2074-81. PubMed ID: 17716890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.
    Fracasso PM; Westervelt P; Fears CL; Rosen DM; Zuhowski EG; Cazenave LA; Litchman M; Egorin MJ
    J Clin Oncol; 2000 Mar; 18(5):1124-34. PubMed ID: 10694566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.
    Giaccone G; Linn SC; Welink J; Catimel G; Stieltjes H; van der Vijgh WJ; Eeltink C; Vermorken JB; Pinedo HM
    Clin Cancer Res; 1997 Nov; 3(11):2005-15. PubMed ID: 9815591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
    Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
    Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations.
    Lum BL; Fisher GA; Brophy NA; Yahanda AM; Adler KM; Kaubisch S; Halsey J; Sikic BI
    Cancer; 1993 Dec; 72(11 Suppl):3502-14. PubMed ID: 7902206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
    Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
    Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.
    Robert F; Chen S; Miller AA; Lee BC; Molthrop DC; Wheeler RH
    Cancer Chemother Pharmacol; 1996; 38(5):459-65. PubMed ID: 8765440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.
    Lum BL; Kaubisch S; Yahanda AM; Adler KM; Jew L; Ehsan MN; Brophy NA; Halsey J; Gosland MP; Sikic BI
    J Clin Oncol; 1992 Oct; 10(10):1635-42. PubMed ID: 1403041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
    Bates S; Kang M; Meadows B; Bakke S; Choyke P; Merino M; Goldspiel B; Chico I; Smith T; Chen C; Robey R; Bergan R; Figg WD; Fojo T
    Cancer; 2001 Sep; 92(6):1577-90. PubMed ID: 11745237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days.
    Thompson DS; Greco A; Miller AA; Srinivas NR; Igwenezue KB; Hainsworth JD; Schacter LP; Kaul S; Barbhaiya RH; Garrow C
    Clin Pharmacol Ther; 1995 May; 57(5):499-507. PubMed ID: 7768072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.